cdmo.directory
← Home
Rezon Bio logo

Rezon Bio

European biologics CDMO for cost-efficient, end-to-end development and manufacturing.

European biologics CDMO offering end-to-end development and manufacturing across two GMP-certified sites in Poland, with capabilities from cell line development to commercial-scale production. Headquartered in Poland.

Modalities

Development & manufacturing

Structured CDMO capabilities from verified public sources.

Biologics / bioreactor infrastructure

Expression systems
Mammalian
Bioreactor type
Stainless Steel
Max bioreactor scale
Large commercial (≤10,000 L)

Services

About this organization

Rezon Bio is a European biologics contract development and manufacturing organization (CDMO) specializing in cost-efficient, scalable solutions for biologics programs. The company operates two GMP-certified facilities in Poland, providing integrated services from early-stage development through commercial manufacturing.

Core Capabilities

  • Process Development & Characterization: Scalable upstream and downstream biologics processes optimized for biosimilars and new biological entities (NBEs) from lab to commercial scale
  • Analytical Capabilities: Phase-appropriate, method-qualified testing for product quality and release
  • GMP Manufacturing: Flexible capacity at clinical and commercial scale, FDA and EMA approved
  • Quality & Regulatory Affairs: Systems aligned with regulatory requirements, confirmed by successful inspections
  • Technology Transfer, MSAT & PPQ: Strategic partnerships for fill/finish enabling "ready to fill" solutions
  • Cell Line Development: End-to-end services from cell line development to commercial manufacturing

Facilities & Scale

The organization operates two sites: a clinical development and manufacturing center with medium-scale capacity, and a large state-of-the-art GMP facility offering commercial-scale manufacturing with 2,000L bioreactors.

Track Record

With over 13 years of biologics development experience, Rezon Bio has completed 12 technology transfers and produced 137 batches since 2024 with a 97% batch success rate. The company has passed 35+ audits from EMA, FDA, MHRA, and ANVISA. The workforce exceeds 1,100 employees, with 80% holding higher education degrees and 10% holding PhDs.

Certifications

AuthorityIdentifierSource
EMAEMA approvedView
FDAFDA approvedView

Locations

  • Headquarters / Clinical Development & Manufacturing

    Poland · Poland

  • Commercial Scale Manufacturing

    Poland · Poland

  • Clinical Development & Manufacturing

    Poland · Poland

  • Commercial Scale Manufacturing

    Poland · Poland

Similar profiles by shared services, modalities, and capabilities.

View all alternatives →See similar CDMOs ranked by shared capabilities

Submit a verified review for this organization.

Markdown mirror: /companies/rezonbio.md